KarXT (xanomeline/trospium) is a novel muscarinic acetylcholine receptor agonist being developed by Bristol-Myers Squibb for the treatment of agitation in Alzheimer's disease (AD). This Phase 3 trial (NCT06585787) is currently recruiting participants to evaluate the efficacy and safety of KarXT in AD patients with clinically significant agitation[1].
Agitation represents one of the most challenging neuropsychiatric symptoms in Alzheimer's disease, affecting up to 70% of patients during the disease course. It includes behaviors such as aggression, restlessness, pacing, and resistiveness to care, significantly impacting quality of life for both patients and caregivers[2].
| Attribute | Details |
|---|---|
| NCT Number | NCT06585787 |
| Sponsor | Bristol-Myers Squibb |
| Drug | KarXT (xanomeline/trospium) |
| Phase | Phase 3 |
| Indication | Agitation in Alzheimer's Disease |
| Status | Recruiting |
| Participants | 406 |
| Study Start | 2024 |
| Estimated Completion | 2026-2027 |
KarXT is a fixed-dose combination of two compounds:
This unique co-formulation allows xanomeline to activate central M1 and M4 receptors while trospium blocks peripheral muscarinic receptors, preventing unwanted side effects such as dry mouth, constipation, and urinary retention[3].
| Receptor | Location | Effect | Therapeutic Implication |
|---|---|---|---|
| M1 | Central | Cognitive enhancement | Memory and learning improvement |
| M4 | Central | Anti-agitation | Reduction of neuropsychiatric symptoms |
| M2/M3 | Peripheral | Autonomic effects | Blocked by trospium |
The selective activation of M1 (cognitive) and M4 (anti-agitation) receptors provides a novel approach that differs from current antipsychotic treatments, which primarily target dopamine and serotonin receptors.
The cholinergic system is severely compromised in Alzheimer's disease:
By activating M1/M4 receptors, KarXT aims to:
Prior Phase 2 trials demonstrated promising results:
The Phase 3 program includes multiple trials (including NCT06585787):
Agitation in AD manifests as:
This symptom significantly increases caregiver burden and is a leading cause of nursing home placement.
| Treatment | Mechanism | Limitations |
|---|---|---|
| Risperidone | D2 antagonist | Extrapyramidal symptoms, stroke risk |
| Quetiapine | Multi-receptor | Sedation, metabolic effects |
| Aripiprazole | Partial D2 agonist | Limited efficacy |
| Benzodiazepines | GABA agonist | Sedation, fall risk, cognitive worsening |
KarXT represents a novel mechanism targeting the cholinergic deficit directly, potentially avoiding these limitations.
BMS acquired Karuna Therapeutics (the original developer of KarXT) in 2023 for approximately $14 billion — representing the largest CNS acquisition in BMS history. This acquisition underscores BMS's strategic commitment to neuropsychiatry and their belief in KarXT's commercial potential.
The AD agitation indication represents a significant market opportunity: